NewAmsterdam Pharma
NAMS
22.13
-0.14
-0.63%
NewAmsterdam Pharma
US · NAMS
#2583 by market cap
Listed 1970
22.13
-0.14
-0.63%
Live - 5344 symbols - heartbeat 514s ago
· 2026-10-08 07:04
Pre-market
22.60
+2.12%
After-hours
22.52
+1.76%
Overnight
22.09
-0.18%
- Market cap
- 2.65B
- P/E (TTM)i
- -10.25
- P/Bi
- 4.19
- EPSi
- -1.72
- Div yieldi
- 0.00%
- 52W posi
- 5%
Reader sentiment
Are you bullish or bearish on NAMS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 17.08, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 6 years
Latest year -50.61% YoY
Margins
- Operating margin
- -1,002.90%
- Net margin
- -905.74%
Key ratios & quality
- Altman Z-Scorei
- 17.08
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | -- | 0 | 102.69M | 14.09M | 45.56M | 22.50M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.52M | 5.68M | 19.51M | 37.63M | 70.45M | 106.35M |
| Research & development | 4.98M | 28.97M | 86.74M | 159.42M | 151.41M | 141.83M |
| Operating profit | -6.49M | -34.65M | -3.56M | -182.97M | -176.29M | -225.68M |
| Pretax profit | -7.07M | -41.79M | -22.63M | -176.91M | -241.60M | -203.82M |
| Tax | 0 | 0 | 0 | 27.00K | -1.00K | 0 |
| Net profit | -7.07M | -41.79M | -22.63M | -176.94M | -241.60M | -203.82M |
| Basic EPS | 0 | -1 | -1 | -2 | -3 | -2 |
| Diluted EPS | -0.09 | -0.51 | -1.19 | -2.15 | -2.56 | -1.72 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.98M | 19.15M | 348.00K | 32.00K | 3.04M | 3.70M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 27.15M | 27.26M | 24.52M | 27.42M | 23.45M | 26.89M |
| Research & development | 44.75M | 27.52M | 30.97M | 38.59M | 38.01M | 41.67M |
| Operating profit | -68.93M | -35.64M | -55.14M | -65.98M | -58.42M | -64.86M |
| Pretax profit | -39.53M | -17.36M | -72.01M | -74.92M | -48.44M | -64.14M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -39.53M | -17.36M | -72.01M | -74.92M | -48.44M | -64.14M |
| Basic EPS | 0 | 0 | -1 | -1 | 0 | -1 |
| Diluted EPS | -0.34 | -0.15 | -0.61 | -0.63 | -0.40 | -0.52 |
Balance sheet
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | 11.34M | 66.66M | 477.98M | 346.79M | 863.41M | 675.70M |
| Cash & ST investments | 9.67M | 60.11M | 467.73M | 340.45M | 834.19M | 636.24M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 11.35M | 67.69M | 478.50M | 347.10M | 864.62M | 769.28M |
| Total current liabilities | 15.75M | 11.19M | 36.06M | 49.90M | 106.92M | 85.79M |
| Short-term debt | 14.33M | 60.01K | 66.00K | 60.00K | 246.00K | 136.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 15,753,222.47 | 11,312,017.39 | 48,431,000.00 | 58,704,000.00 | 107,120,000.00 | 85,853,000.00 |
| Total equity | -4.40M | 56.37M | 430.07M | 288.39M | 757.50M | 683.43M |
| Retained earnings | -7.47M | -39.26M | -140.04M | -316.97M | -558.57M | -762.39M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 817.30M | 769.85M | 732.33M | 675.70M | 658.04M | 659.21M |
| Cash & ST investments | 808.48M | 739.16M | 702.95M | 636.24M | 636.11M | 633.85M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 818.41M | 815.11M | 786.43M | 769.28M | 732.64M | 704.45M |
| Total current liabilities | 40.91M | 36.51M | 58.27M | 85.79M | 67.42M | 72.97M |
| Short-term debt | 252.00K | 225.00K | 181.00K | 136.00K | 23.00K | 26.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 41,050,000.00 | 36,615,000.00 | 58,357,000.00 | 85,853,000.00 | 67,421,000.00 | 73,030,000.00 |
| Total equity | 777.36M | 778.50M | 728.07M | 683.43M | 665.22M | 631.42M |
| Retained earnings | -598.10M | -615.46M | -687.47M | -762.39M | -810.83M | -874.97M |
Cash flow
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -7.34M | -29.51M | 10.67M | -141.22M | -158.56M | -147.78M |
| Depreciation & amortization | 1.23K | 5.00K | 9.00K | 49.00K | 113.00K | 220.00K |
| Free cash flow | -7.36M | -29.54M | 10.44M | -141.24M | -159.24M | -148.03M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 84.70M | 396.95M | 0 | 645.51M | 0 |
| Ending cash balance | 9.67M | 60.13M | 467.73M | 340.45M | 771.74M | 491.32M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -36.47M | -37.67M | -32.77M | -40.88M | -30.60M | -39.21M |
| Depreciation & amortization | 52.00K | 45.00K | 64.00K | 59.00K | 62.00K | 59.00K |
| Free cash flow | -36.48M | -37.76M | -32.81M | -40.98M | -30.64M | -39.29M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 748.42M | 563.86M | 539.72M | 491.32M | 458.94M | 425.51M |
Returns & efficiency
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -124.60 | -29.06 | -43.80 | -46.20 | -28.29 |
| ROA %i | -62.28 | -81.93 | -26.25 | -38.58 | -39.88 | -24.95 |
| ROIC %i | -- | -96.70 | -28.95 | -45.86 | -49.40 | -32.11 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -58.77 |
| EBIT margin %i | -- | -- | -79.78 | -1,255.57 | -530.25 | -1,002.90 |
| FCF / sales %i | -- | -- | 8.16 | -- | -- | -- |
| Current ratioi | 0.72 | 5.96 | 13.26 | 6.95 | 8.08 | 7.88 |
| Quick ratioi | 0.72 | 5.81 | 13.03 | 6.86 | 8.00 | 7.69 |
| Debt / assetsi | 126.21 | 0.27 | 0.03 | 0.02 | 0.05 | 0.03 |
| LT debt / equityi | -- | 0.22 | 0.01 | -- | 0.03 | 0.01 |
| Interest coveragei | -15.71 | -131.40 | -287.01 | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -39.71 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -31.51 | -28.43 | -39.94 | -28.29 | -29.49 | -36.81 |
| ROA %i | -28.67 | -26.27 | -36.08 | -24.95 | -27.43 | -34.16 |
| ROIC %i | -35.05 | -32.40 | -44.54 | -32.11 | -33.07 | -40.30 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -541.03 | -372.00 | -761.12 | -1,002.90 | -953.59 | -3,432.20 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 19.98 | 21.08 | 12.57 | 7.88 | 9.76 | 9.03 |
| Quick ratioi | 19.80 | 20.79 | 12.41 | 7.69 | 9.56 | 8.76 |
| Debt / assetsi | 0.05 | 0.04 | 0.03 | 0.03 | 0.00 | 0.01 |
| LT debt / equityi | 0.02 | 0.01 | 0.01 | 0.01 | -- | 0.01 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovery, development and commercialization of transformative therapies for cardio-metabolic100.00%
Quote time 2026-10-08 07:04:28 · For reference only, not investment advice and not tailored to your situation.